ALISO VIEJO, Calif.
March 19, 2014
Avanir Pharmaceuticals, Inc.
(NASDAQ: AVNR) today announced the appointment of Dr.
to the company's board of directors. Dr. Corrigan, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience.
Dr. Corrigan currently serves as president and chief executive officer of Zalicus Inc. a public biopharmaceutical company, a position he has held since
. He has also served as a director of Zalicus and its progenitor companies since
. Prior to Zalicus, Dr. Corrigan served as executive vice president, research and development at Sepracor, Inc. (now known as Sunovion Pharmaceuticals, Inc.). Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, a pharmaceutical company acquired by Pfizer, Inc. in 2003, most recently as group vice president of Global Clinical Research and Experimental Medicine. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the
University of North Carolina
Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan has also been a member of the board of directors and audit committee of Cubist Pharmaceuticals, Inc. since
. Dr. Corrigan holds a B.A. and an M.D. from the
University of Virginia
and subsequently received specialty training in Psychiatry at
and Maine Medical Center.
"It is a pleasure to welcome Mark to the Avanir Board," commented
, chairman of the board, "Mark brings many years of experience in the healthcare sector combined with a deep knowledge of CNS research and development together with broad experience in guiding the growth of biopharma companies. I look forward to the insights he will bring to our board and to working with him as Avanir pursues its growth initiatives."
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit
is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in
the United States
and other countries.
©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.